Latest Content

Herceptin, Perjeta Regimen May Be Effective Without Chemo in Breast Cancer

October 2nd 2024, 9:00pm

By Sabrina Serani

Article

Among patients with HR+/HER2+ breast cancer, Herceptin and Perjeta plus endocrine therapy proved to be beneficial without chemotherapy.

Gleevec Interruption in GIST Associated with Resistance, Recurrence, Death

October 2nd 2024, 7:00pm

By Alex Biese

Article

Researchers are advising against the interruption of treatment with Gleevec among patients with advanced gastrointestinal stromal tumors.

Cancer Makes Me Look at Life Differently

October 2nd 2024, 5:00pm

By Linda Cohen

Article

After recently losing my aunt, I realized that cancer has given me a new perspective on life, which reminds me that every day has meaning.

Hypofractionated Preoperative RT May Be Safe And Effective in Soft Tissue Sarcoma

October 2nd 2024, 3:00pm

By Spencer Feldman

Article

Patients with soft tissue sarcomas showed improved functional results, quality of life and fewer side effects when treated with RT-therapy.

Longer Time Until Recurrence Associated With Better Melanoma Outcomes

October 2nd 2024, 1:00pm

By Alex Biese

Article

An expert explains study findings that associate a longer time until postsurgical melanoma recurrence with improved progression and survival.

Long-Term Study Data Support Keytruda as Standard of Care for Advanced Melanoma

October 1st 2024, 9:00pm

By Kristi Rosa

Article

Keytruda continued to improve survival versus Yervoy in unresectable stage 3 or 4 melanoma in long-term follow-up data.

Theranostics a ‘State-of-the-Art’ Treatment Option for Prostate Cancer

October 1st 2024, 7:00pm

By Ashley Chan

Article

For patients with prostate cancer, theranostics may be another available treatment path to take, especially for those who need more options.

Bracing for the Impact of Pinktober for Breast Cancer

October 1st 2024, 5:00pm

By Bonnie Annis

Article

As a breast cancer survivor, I’ve learned to navigate the annual sea of pink, but I don’t like it.

Oncology Drugs Approved by the FDA in September 2024

October 1st 2024, 3:00pm

By Darlene Dobkowski, MA

Article

Throughout September, the FDA approved drugs for the treatment of diseases including lung cancer, multiple myeloma, thyroid cancer and breast cancer.

Fotivda Shows Better Outcomes Than Combo in Metastatic Kidney Cancer

October 1st 2024, 1:00pm

By Megan Hollasch

Article

Fotivda monotherapy may show better outcomes in second-line therapy than the combination of Opdivo and Fotivda in metastatic kidney cancer.

Anti-PD-L1 Antibody Drug Combo May Improve Outcomes in Advanced Kidney Cancer

September 30th 2024, 9:00pm

By Kyle Doherty

Article

Benmelstobart plus anlotinib significantly improved survival versus Sutent in the first-line treatment of advanced renal cell carcinoma.

Celebrating 4 Years Cancer-Free

September 30th 2024, 5:00pm

By Carla Deschamps

Article

I invited my family to gather with me and celebrate four years of being cancer-free.

NBA Star Dikembe Mutombo Dies of Brain Cancer

September 30th 2024, 3:58pm

By Alex Biese

Article

The Hall of Famer has died from brain cancer at the age of 58, the NBA has announced.

Chemo Shortage Increases Treatment Costs by 16% for Head and Neck Cancer

September 30th 2024, 3:00pm

By Darlene Dobkowski, MA

Article

In addition to increased treatment costs, patients with head and neck cancers also experienced therapy changes during the cisplatin shortage.

Lower Keytruda Doses May Be as Effective as Standard Doses for Stage 4 NSCLC

September 30th 2024, 1:00pm

By Spencer Feldman

Article

Patients with stage 4 non-small cell lung cancer may derive an equal benefit with a lower dose of Keytruda versus the standard dose.